Collaborative and Other Relationships Collaborative and Other Relationships (Tables)

3 Months Ended

Mar. 31, 2019

A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:



	For the Three Months Ended March 31,
(In millions)	2019		2018
Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat	$	68.0	$	52.2
Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income	$	34.0	$	26.1

A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:



	For the Three Months Ended March 31,
(In millions)	2019		2018
Total aducanumab development expense	$	162.5	$	63.6
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income	$	89.4	$	63.6

Total aducanumab sales and marketing expense incurred by the collaboration	$	20.9	$	7.1
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income	$	11.6	$	3.9